Last reviewed · How we verify

NORTASE® — Competitive Intelligence Brief

NORTASE® (NORTASE®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Matrix-degrading enzyme / Tumor microenvironment modifier. Area: Oncology.

phase 3 Matrix-degrading enzyme / Tumor microenvironment modifier Extracellular matrix proteins (collagen) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

NORTASE® (NORTASE®) — University of Leipzig. NORTASE is an enzyme-based therapeutic that degrades extracellular matrix components to improve drug penetration and immune cell infiltration in solid tumors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NORTASE® TARGET NORTASE® University of Leipzig phase 3 Matrix-degrading enzyme / Tumor microenvironment modifier Extracellular matrix proteins (collagen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Matrix-degrading enzyme / Tumor microenvironment modifier class)

  1. University of Leipzig · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NORTASE® — Competitive Intelligence Brief. https://druglandscape.com/ci/nortase. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: